HALIFAX, Nova Scotia, July 03, 2026 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”),…
LIKMEZ® (ATI-1501) commercial momentum building in U.S. marketUS$40 million NIAID award supporting VXV-01 advancement through Phase 1 HALIFAX, Nova Scotia,…
US$82 Million in Pending Proposals Across Multiple Infectious Disease Programs US$40 Million NIAID Funding Award Supports VXV-01 Development Through Phase…